Agilent partners with NUS to advance cardiovascular research in Singapore

The collaboration will span four years.

Agilent Technologies has entered into a strategic partnership with the National University of Singapore (NUS), through NUS Medicine, to establish a Center of Excellence in Cell Metabolism.

The collaboration aims to advance research in cardiovascular and metabolic diseases over the next four years.

Agilent’s integrated metabolic and cellular phenotyping platforms, such as xCELLigence, Seahorse XF, and BioTek technologies enable efficient cell studies. This will facilitate the discovery of new therapeutic targets and cardio-liver-metabolic biomarkers to prevent CVDs.

According to GlobalData, global partnerships are expected to strengthen NUS’ Project RESET, which aims to advance cardiovascular research in the country.

“By developing innovative, preventative healthcare strategies and enhancing local expertise in cardiovascular research, Singapore aims to reduce healthcare costs associated with CVDs. Furthermore, international collaborations will elevate Singapore’s status as a hub for biomedical research, attracting investment, talent, and boosting the local economy over time,” Shreya Jain, Medical Devices Analyst at GlobalData said.

Follow the link for more news on

National University of Singapore

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia